EMA: ABEL for HVD(P)s, PK metrics [Regulatives / Guidelines]

posted by Pharma_88 – India, 2020-09-08 11:05 (1323 d 18:36 ago) – Posting: # 21910
Views: 6,510

Thanks For your detailed response.

I have a few questions and need your suggestion in this regards.

I have kept following parameters in SS study (IR VS ER).

Primary pharmacokinetic parameters: AUC0-τ,ss
Secondary pharmacokinetic parameters:
Day 01 to 04-Morning dose: Cpd
Day 04 (Morning dose): Cτ,ss, Cmax,ss, Cmin,ss, Tmax,ss, accumulation index, %Fluctuation and Cav

Please correct me.

and also want to know for Cpd and Cτ,ss:

Cpd: All pre-dose samples needs to be considered including profiling day sample or only samples before profiling day?

Cτ,ss: How to calculate it? Whether morning dose of Day 04 is also need to be taken in to account to calculate.

Thanks.

Complete thread:

UA Flag
Activity
 Admin contact
22,993 posts in 4,828 threads, 1,657 registered users;
65 visitors (0 registered, 65 guests [including 5 identified bots]).
Forum time: 05:41 CEST (Europe/Vienna)

So far as I can remember,
there is not one word in the Gospels
in praise of intelligence.    Bertrand Russell

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5